Onco-cardiology is an emerging interdiscipline that integrates the fields of malignant tumors and cardiovascular diseases

and its development in China is in the ascendant. At present

cardiovascular adverse reactions caused by antineoplastic drugs are still the research focus in this discipline

especially cardiovascular toxicity caused by chemotherapeutic drugs such as anthracyclines

targeted therapeutic drugs such as human epidermal growth factor receptor 2 inhibitors and immunotherapy drugs such as immune checkpoint inhibitors. Primary prevention and early treatment for cardiovascular toxicity of antineoplastic drugs are important measures to improve the prognosis of patients with onco-cardiological disease. With the progress of discipline of onco-cardiology

basic research is gradually implemented into clinical practice in the form of translational medicine

patients benefit not only limited to the remission and improvement of cardiovascular toxicity from antineoplastic therapy

but also the optimization and adjustment of treatment plan for basic cardiovascular disease in tumor patients. In the onco-cardiological multidisciplinary treatment teams

clinical pharmacists can assist clinical teams in formulating and adjusting patients’ treatment plans by reducing medication errors

warning drug interactions

providing pharmacogenomic information and therapeutic drug management

so as to carry out individualized and precise treatment

reduce toxicity and increase effectiveness.